-+ 0.00%
-+ 0.00%
-+ 0.00%

Zenas BioPharma to present Phase 3 INDIGO open-label extension data on obexelimab in IgG4-related disease at IgG4ward symposium

PUBT·09/22/2026 11:07:13
Zenas BioPharma to present Phase 3 INDIGO open-label extension data on obexelimab in IgG4-related disease at IgG4ward symposium
  • Zenas Biopharma scheduled new Phase 3 INDIGO obexelimab updates in IgG4-related disease for October 8-10, 2026, then ACR Convergence 2026.
  • Results will be presented in the future, including longer-term flare protection and safety from the INDIGO open-label extension.
  • Separate analyses are set to show reduced glucocorticoid-associated toxicity in the randomized, placebo-controlled INDIGO trial.
  • Another presentation will address whether patients maintained clinically meaningful influenza and SARS‑CoV‑2 vaccine responses during a treatment-free window.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220705PRIMZONEFULLFEED9831074) on September 22, 2026, and is solely responsible for the information contained therein.